Meeting
2018 Gastrointestinal Cancers Symposium
Phase II trial of oral S-1 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard chemotherapies (CCOG-1105 study).
Authors
Kazuhiro Ezaka
Nagoya University Hospital, Nagoya, Japan
Kazuhiro Ezaka , Goro Nakayama , Hiroyuki Yokoyama , Takanori Matsui , Shinichi Umeda , Yuki Sunagawa , Kenta Murotani , Yuichi Ando , Yasuhiro Kodera
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
UMIN000006476
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 841)
DOI
10.1200/JCO.2018.36.4_suppl.841
Abstract #
841
Poster Bd #
N17
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase II study of lenvatinib in patients with metastatic colorectal cancer refractory to standard chemotherapy: LEMON study (NCCH1503).
First Author: Hirokazu Shoji
Poster
2014 Gastrointestinal Cancers Symposium
Phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pretreated patients with metastatic colorectal cancer.
First Author: Kazuhisa Yamaguchi
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world effectiveness and safety of trifluridine-tipiracil (FTD/TPI) and bevacizumab (BEV) in refractory metastatic colorectal cancer (mCRC): The BeTAS trial.
First Author: Nieves Martinez Lago
Poster
2024 ASCO Gastrointestinal Cancers Symposium
HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer (mCRC) refractory to anti-EGFR antibodies.
First Author: Atsushi Ishiguro